Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.67 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081346 | 1.00 | DRD3 (0.67) | DRD3DRD2KDM2BPABPC1CNR2 | |
| SCHEMBL2077442 | 0.87 | DRD3 (0.70) | DRD3DRD2KDM2BCNR2 | |
| SCHEMBL2081330 | 0.80 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2080310 | 0.80 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2080308 | 0.80 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2078759 | 0.77 | DRD3 (0.58) | DRD3CNR2 | |
| SCHEMBL2077562 | 0.77 | DRD3 (0.71) | DRD3DRD2 | |
| SCHEMBL2936540 | 0.77 | DRD3 (0.71) | DRD3DRD2CNR2 | |
| SCHEMBL12947908 | 0.75 | DRD3 (0.63) | DRD3DRD2CNR2 | |
| SCHEMBL25691716 | 0.75 | DRD3 (0.60) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | PFIZER INC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | DBH, OPRM1, CHRM1 | DRD3 19/4885DRD2 10/4885KDM2B 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.